药物基因组学与口服降糖药  

Pharmacogenomics and oral hypoglycemic agents

作　　者：蒋晶晶[1] 刘超[1] 

机构地区：[1]南京医科大学第一附属医院内分泌科,210029

出　　处：《国际内分泌代谢杂志》2007年第2期81-83,共3页International Journal of Endocrinology and Metabolism

摘　　要：药物基因组学主要研究不同个体对药物的反应如何受基因的影响，目前的研究热点主要包括药物的受体、代谢酶、转运体及疾病相关通路基因的多态性对药物作用的影响。口服降糖药是治疗2型糖尿病的重要手段，不同的遗传背景可能通过影响药物的作用和代谢导致对口服降糖药反应的差异。研究糖尿病相关的药物基因组学，有助于根据特定的基因型选择合适的降糖药，对于个体化用药、提高疗效、减少副反应等都具有重要意义。Pharmacogenomics is mainly used to study the effect of gene on the drug response of different individuals. Recently, the hot spots of pharmacogenomics include the receptor of drug, metabolic enzymes, transporters and the gene polymorphisms related to signal pathway in disease. Oral hypoglycemic agents are widely used in treating type 2 diabetes. Different genetic background results in the different response to oral hypoglycemic agents of individual by influencing the effect and metabolism of drug. The research of phannacogenomics related to diabetes attributes to select the appropriate hypoglycemic agents according to specific genotype. And it is of great significance in personalized medication, enhancing the efficacy, reducing the side effects.

关 键 词：药物基因组学 口服降糖药 糖尿病 

分 类 号：R587[医药卫生—内分泌]